Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients
- 806 Downloads
The presence of a bulky tumour at staging on CT is an independent prognostic factor in malignant lymphomas. However, its prognostic value is limited in diffuse disease. Total metabolic tumour volume (TMTV) determined on 18F-FDG PET/CT could give a better evaluation of the total tumour burden and may help patient stratification. Different methods of TMTV measurement established in phantoms simulating lymphoma tumours were investigated and validated in 40 patients with Hodgkin lymphoma and diffuse large B-cell lymphoma.
Data were processed by two nuclear medicine physicians in Reggio Emilia and Créteil. Nineteen phantoms filled with 18F-saline were scanned; these comprised spherical or irregular volumes from 0.5 to 650 cm3 with tumour-to-background ratios from 1.65 to 40. Volumes were measured with different SUVmax thresholds. In patients, TMTV was measured on PET at staging by two methods: volumes of individual lesions were measured using a fixed 41 % SUVmax threshold (TMTV41) and a variable visually adjusted SUVmax threshold (TMTVvar).
In phantoms, the 41 % threshold gave the best concordance between measured and actual volumes. Interobserver agreement was almost perfect. In patients, the agreement between the reviewers for TMTV41 measurement was substantial (ρ c = 0.986, CI 0.97 – 0.99) and the difference between the means was not significant (212 ± 218 cm3 for Créteil vs. 206 ± 219 cm3 for Reggio Emilia, P = 0.65). By contrast the agreement was poor for TMTVvar. There was a significant direct correlation between TMTV41 and normalized LDH (r = 0.652, CI 0.42 – 0.8, P <0.001). Higher disease stages and bulky tumour were associated with higher TMTV41, but high TMTV41 could be found in patients with stage 1/2 or nonbulky tumour.
Measurement of baseline TMTV in lymphoma using a fixed 41% SUVmax threshold is reproducible and correlates with the other parameters for tumour mass evaluation. It should be evaluated in prospective studies.
KeywordsMetabolic volume Lymphoma Prognosis PET/CT
Conception and design
Michel Meignan, Annibale Versari, Stefano Luminari, Francesco Merli, Paolo G. Gobbi, Olivier Casasnovas.
Collection and assembly of data
Data analysis and interpretation
Myriam Sasanelli, Annibale Versari, Michel Meignan, Federica Fioroni, Chiara Coriani, Olivier Casasnovas, Emmanuel Itti.
Michel Meignan, Annibale Versari, Olivier Casasnovas.
Final approval of manuscript
Conflicts of interest
- 2.Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9:435–44.PubMedCrossRefGoogle Scholar
- 3.Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22.PubMedCrossRefGoogle Scholar
- 11.Mikhaeel NG, Smith D, Philips MM, Dunn JT, Fields PA, Moller H, et al. Does quantitative PET-CT predict prognosis in diffuse large B cell lymphoma. Hematol Oncol. 2013;31 Suppl 1:96–150.Google Scholar
- 15.Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.PubMedCrossRefGoogle Scholar
- 19.McBride GB. A proposal for strength of agreement criteria for Lin’s concordance correlation coefficient. NIWA Client Report HAM2005-062. Hamilton, New Zealand: National Institute of Water & Atmospheric Research Ltd; 2005.Google Scholar
- 25.Sasanelli M, Itti E, Biggi A, Berriolo-Riedinger A, Cashen A, Tilly H, et al. Prognostic value of pretherapy metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with diffuse large B-cell lymphoma (DLBCL). J Nucl Med. 2012;53:170P.Google Scholar
- 26.Casasnovas RO, Sasanelli M, Berriolo-Riedinger A, Morschhauser F, Itti E, Huglo D, et al. Baseline metabolic tumor volume is predictive of patient outcome in diffuse large B cell lymphoma. Blood. 2012;120:1598.Google Scholar
- 30.Kanoun SRC, Berriolo-Riedinger A, Humbert O, Dygay-Cochet I, Chretien ML, Legouge C, et al. Metabolic tumor volume is an independent prognosis factor predicting patient’s outcome in Hodgkin lymphoma. Blood. 2012;120:3631.Google Scholar
- 31.Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342–8.PubMedGoogle Scholar